Trials / Available
AvailableNCT07422389
BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
Intermediate-Size Patient Population Use of BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- BRIM Biotechnology Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops. Participants will: * Use BRM421 two times a day for at least 12 weeks * Visit the clinic monthly for checkups and tests
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BRM421 Ophthalmic Solution, 0.06% | Patients eligible to participate will receive 0.06% BRM421 Ophthalmic Solutions to be administered two times daily (BID, morning and bedtime) on the eligible eye(s). The administration will be at least 12 weeks. The investigator may continue the treatment beyond the 12 weeks based on clinical response. For patients scheduled for LSC transplant, treatment with BRM421 should start only after surgery. |
Timeline
- First posted
- 2026-02-20
- Last updated
- 2026-02-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07422389. Inclusion in this directory is not an endorsement.